MAY 22, 2017 10:00 AM PDT
WEBINAR: The clinical impact and implementation of T2MR and the T2Candida Panel in the management of candidemia at a large tertiary care health system
SPONSORED BY: T2 Biosystems, Inc.
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
4 15 2242

Speakers:
  • Senior Staff Physician Director, Transplant Infectious Diseases , Medical Director of Infection Prevention, Henry Ford Hospital; Professor of Medicine, Wayne State University
    Biography
      Dr. Alangaden received his medical degree from the University of Bombay and has since completed post-graduate training in India, the United Kingdom and the United States. Dr. Alangaden is the Director of Transplant Infectious Diseases and Director of Infection Control and Prevention at Henry Ford Hospital and Transplant Institute.

      Dr. Alangaden's research interest lies in the epidemiology and outcomes of infections in immunocompromised patients and transplant recipients. He is also involved and well-published in the areas of research related to tuberculosis and nosocomial infections especially, Clostridium difficile.

    Abstract:

    DATE: May 22, 2017
    TIME: 10:00am PT, 1:00pm ET

    Learn from renowned clinical expert, George J. Alangaden, M.D., as he discusses how Henry Ford Health System (HFHS) implemented T2MR and the T2Candida Panel as part of their sepsis protocol for the management of candidemia. Dr. Alangaden will also share the positive impact T2MR and T2Candida has had at HFHS on patient length of stay and antifungal use.  

    Learning Objectives:

    • Understand the process for implementation of T2MR and the T2Candida Panel at the Henry Ford Health System (HFHS)
    • Understand the impact of T2Candida Panel on the management of patients with candidemia at HFHS

    Show Resources
    Loading Comments...